Pier Capital LLC Purchases 71,851 Shares of Guardant Health, Inc. (NASDAQ:GH)

Pier Capital LLC lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 45.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 230,280 shares of the company's stock after purchasing an additional 71,851 shares during the quarter. Pier Capital LLC owned 0.19% of Guardant Health worth $7,035,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GH. Arizona State Retirement System raised its position in shares of Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after purchasing an additional 817 shares in the last quarter. Fiduciary Alliance LLC raised its stake in Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after purchasing an additional 836 shares in the last quarter. R Squared Ltd bought a new stake in Guardant Health during the fourth quarter valued at approximately $26,000. Finally, Van ECK Associates Corp grew its stake in Guardant Health by 47.4% in the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock worth $88,000 after buying an additional 929 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Stock Performance

GH stock traded down $2.01 on Friday, reaching $43.14. The company's stock had a trading volume of 1,168,890 shares, compared to its average volume of 2,167,286. The business has a fifty day simple moving average of $44.66 and a two-hundred day simple moving average of $34.30. The firm has a market cap of $5.32 billion, a PE ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on GH shares. Guggenheim reiterated a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a research report on Monday, February 24th. Piper Sandler increased their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Scotiabank upped their target price on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Stifel Nicolaus lifted their price target on shares of Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Barclays began coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 target price on the stock. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.